SLN

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Wall Street analysts forecast SLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLN is 75.00 USD with a low forecast of 75.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Silence Therapeutics PLC revenue for the last quarter amounts to 159.00K USD, decreased -89.29 % YoY.

Silence Therapeutics PLC. EPS for the last quarter amounts to -0.15 USD, decreased -40.00 % YoY.

Silence Therapeutics PLC (SLN) has 116 emplpoyees as of January 10 2026.

Today SLN has the market capitalization of 260.73M USD.